Sebastian Dintner
Overview
Explore the profile of Sebastian Dintner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Reitsam N, Markl B, Dintner S, Sipos E, Grochowski P, Grosser B, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765951
Background: Recently, our group introduced Stroma AReactive Invasion Front Areas (SARIFA) as an independent prognostic predictor for a poorer outcome in colon cancer patients, which is probably based on immunologic...
12.
Markl B, Dintner S, Schaller T, Sipos E, Kling E, Miller S, et al.
Int J Infect Dis
. 2022 Dec;
128:51-57.
PMID: 36584746
Objectives: Omicron lineages BA.1/2 are considered to cause mild clinical courses. Nevertheless, fatal cases after those infections are recognized but little is known about risk factors. Methods: A total of...
13.
Rentschler L, Markl B, Schaller T, Hirschbuhl K, Kleinlein I, Dintner S, et al.
Pathol Res Pract
. 2022 Dec;
241:154263.
PMID: 36527838
Objectives: The decreasing autopsy numbers in many western countries have been partially attributed to the invasiveness of the autopsy, which causes relatives to decline postmortem examination. This issue has been...
14.
Reitsam N, Markl B, Dintner S, Waidhauser J, Vlasenko D, Grosser B
Front Oncol
. 2022 Nov;
12:1019798.
PMID: 36387226
Immunohistochemical analysis of mismatch repair (MMR) protein expression is widely used to identify tumors with a deficient MMR (dMMR). MMR proteins (MLH1/PMS2 and MSH2/MSH6) work as functional heterodimers, which usually...
15.
Luke F, Haller F, Utpatel K, Krebs M, Meidenbauer N, Scheiter A, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291825
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the...
16.
Schwierzeck V, Effner R, Abel F, Reiger M, Notheis G, Held J, et al.
J Clin Immunol
. 2022 Jun;
42(6):1301-1309.
PMID: 35655107
Hyper-IgE syndromes (HIES) are a group of inborn errors of immunity (IEI) caused by monogenic defects such as in the gene STAT3 (STAT3-HIES). Patients suffering from HIES show an increased...
17.
Christopoulos P, Kluck K, Kirchner M, Luders H, Roeper J, Falkenstern-Ge R, et al.
Eur J Cancer
. 2022 May;
170:106-118.
PMID: 35598358
Background: EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce....
18.
Hirschbuhl K, Schaller T, Markl B, Claus R, Sipos E, Rentschler L, et al.
Mod Pathol
. 2022 Apr;
35(8):1013-1021.
PMID: 35365771
The rate of SARS-CoV-2 infections in vaccinees has become a relevant serious issue. This study aimed to determine the causes of death, histological organ alteration, and viral spread in relation...
19.
Gluckstein M, Dintner S, Miller S, Vlasenko D, Schenkirsch G, Agaimy A, et al.
Diagnostics (Basel)
. 2022 Feb;
12(2).
PMID: 35204520
ALK, NUT, and TRK are rare molecular aberrations that are pathognomonic for specific rare tumors. In low frequencies, however, they are found in a wide range of other tumor entities....
20.
Brandner J, Boor P, Borcherding L, Edler C, Gerber S, Heinemann A, et al.
Virchows Arch
. 2022 Jan;
480(3):519-528.
PMID: 34993593
Confronted with an emerging infectious disease at the beginning of the COVID-19 pandemic, the medical community faced concerns regarding the safety of autopsies on those who died of the disease....